News Sentiment

KURA sentiment intelligence

Kura Oncology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 11.45 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+3.2% over one week, +26.5% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Kura Oncology to Present First Long-Term Follow-Up Data

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 3.2% Price confirming higher
Trend fit Trend active 26.5% over four weeks
Fair value -5.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 31
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 7
GlobeNewswire 6
simplywall.st 6
Stock Titan 3
TradingKey 3
Stock Traders Daily 2
Simply Wall St. 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 27
Regulatory and legal 2
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
GlobeNewswire Direct company coverage

Kura Oncology to Present First Long-Term Follow-Up Data

Kura Oncology will present updated Phase 1a results from its FIT-001 clinical trial at the 2026 Kidney Cancer Research Summit, showcasing long-term follow-up data for darlifarnib in combination with cabozantinib for advanced renal cell carcinoma. The data aims to support darlifar

Tone
Positive 72/100
Event
Earnings
Published
14 Jul 2026 19:13
Source
GlobeNewswire
TradingView Direct company coverage

Enterprise value to revenue forward of Kura Oncology, Inc. – NASDAQ:KURA

This article provides a specific financial metric, "Enterprise value to revenue forward," for Kura Oncology, Inc. (NASDAQ: KURA). It is presented within the context of TradingView's financial data offerings, indicating the company's listing on the Nasdaq Stock Market. The content

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 16:14
Source
TradingView
Pluang Direct company coverage

Kura Oncology presents new data supporting darlifarnib's role in enhancing kidney cancer therapy.

Kura Oncology released updated Phase 1a results from its FIT-001 trial, showing that darlifarnib combined with cabozantinib improved outcomes for advanced clear cell renal cell carcinoma (ccRCC) patients. These findings suggest darlifarnib enhances VEGFR-targeted therapies, with

Tone
Positive 92/100
Event
Earnings
Published
14 Jul 2026 11:14
Source
Pluang
GlobeNewswire Direct company coverage

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Kura Oncology announced it will present updated Phase 1a results from the FIT-001 clinical trial evaluating darlifarnib in combination with cabozantinib at the 2026 Kidney Cancer Research Summit. These long-term follow-up data in advanced renal cell carcinoma patients are expecte

Tone
Positive 72/100
Event
Earnings
Published
14 Jul 2026 11:14
Source
GlobeNewswire
TradingView Direct company coverage

Price to earnings forward of Kura Oncology, Inc. – NASDAQ:KURA

This article provides a financial listing for Kura Oncology, Inc. (NASDAQ: KURA) on TradingView, focusing on its price to earnings forward. It shows the company's stock information, market status, and available financial data points.

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 20:11
Source
TradingView
Stock Traders Daily Direct company coverage

(KURA) and the Role of Price-Sensitive Allocations

This article provides a detailed analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct AI-generated trading strategies tailored for different risk profiles: Po

Tone
Positive 66/100
Event
Market update
Published
11 Jul 2026 02:20
Source
Stock Traders Daily
TradingView Direct company coverage

Price to sales forward of Kura Oncology, Inc. – NASDAQ:KURA

This article displays the "Price to sales forward" metric for Kura Oncology, Inc. (NASDAQ: KURA). It provides a snapshot of this financial data point for the company, accessible through TradingView's financial analysis tools. The content focuses solely on presenting this particul

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 08:10
Source
TradingView
AD HOC NEWS Direct company coverage

Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones

Kura Oncology Inc. is a biotech company focused on developing targeted therapies for difficult-to-treat cancers. The company's strategy involves advancing small-molecule drugs through clinical trials for genetically defined cancer subsets, a common approach in the US oncology sec

Tone
Positive 70/100
Event
Regulatory and legal
Published
07 Jul 2026 14:11
Source
AD HOC NEWS
Stock Titan Direct company coverage

Kura Oncology offers stock options to five new hires

Kura Oncology announced the grant of nonstatutory stock options for 68,750 shares to five new employees on July 1, 2026, with an exercise price of $10.78 per share. These inducement grants are made under the company's 2023 Inducement Option Plan, as amended, and align with Nasdaq

Tone
Positive 71/100
Event
Market update
Published
03 Jul 2026 11:39
Source
Stock Titan
GlobeNewswire Direct company coverage

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards to five new employees. These awards consist of nonstatutory stock options to purchase 68,750 shares of common stock, with an exercise price of $10.78 per share, vesting over four years. This a

Tone
Positive 65/100
Event
Market update
Published
03 Jul 2026 11:39
Source
GlobeNewswire
Benzinga Direct company coverage

Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript

Kura Oncology reported Q1 2026 net product revenue of $5.8 million for Comzifty, exceeding expectations in its first full quarter since commercial launch. The company emphasizes expanding Comzifty's use across the AML treatment spectrum, including combination therapies, and antic

Tone
Positive 72/100
Event
Earnings
Published
02 Jul 2026 06:12
Source
Benzinga
www.marketscreener.com Direct company coverage

Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark

Kura Oncology, Inc. (NasdaqGS:KURA) has been added to the Russell Small Cap Comp Growth Benchmark, along with the Russell 2500 Growth and Russell 3000E Growth Benchmarks. The biopharmaceutical company, focused on precision medicine for cancer treatment, was also dropped from the

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 21:48
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark

Kura Oncology, Inc. (NasdaqGS: KURA) has been added to the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This inclusion reflects the company's growth trajectory and highlights its position within the small-cap growth market. Kura Oncology is a clinical-stage bioph

Tone
Positive 77/100
Event
Market update
Published
29 Jun 2026 19:09
Source
www.marketscreener.com
Statista Direct company coverage

Kura Oncology, Inc. liabilities 2021-2025

This article from Statista presents data on the liabilities of Kura Oncology, Inc. from 2021 to 2025. The company's liabilities are reported to have continuously increased from 2021 to 2025, reaching a specific amount in 2025, according to data from their fiscal year ending Decem

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 14:10
Source
Statista
TradingView Direct company coverage

Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA)

This article provides an overview of Kura Oncology, Inc. (NASDAQ: KURA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent financial results, su

Tone
Positive 61/100
Event
Earnings
Published
26 Jun 2026 13:43
Source
TradingView
TradingView Direct company coverage

Kura Oncology, Inc. Actuals & Estimates (DUS:KUR)

This article provides an overview of Kura Oncology, Inc. (DUS:KUR) stock, including financial data, analyst estimates, historical prices, and future earnings reports. It details the company's past earnings and revenue, current EBITDA, and confirms that it does not pay dividends.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Kura Oncology, Inc. Actuals & Estimates (HAM:KUR)

This article provides an overview of Kura Oncology, Inc. (HAM:KUR) financial data, analyst estimates, and stock performance. It includes details on revenue, earnings, EBITDA, stock forecasts, and historical price movements, alongside answers to frequently asked questions about th

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
Moomoo Direct company coverage

Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness

Kura Oncology (NASDAQ:KURA) saw its insiders sell US$1.5 million worth of stock over the last year, indicating a potential weakness in the company's outlook. This sell-off occurred despite a generally flat share price, with analysts expecting the company to become profitable in t

Tone
Negative 38/100
Event
Guidance
Published
23 Jun 2026 14:09
Source
Moomoo
Investing.com South Africa Direct company coverage

Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com

Mollie Leoni, CMO of Kura Oncology, sold 84,929 shares of company stock for approximately $834,283. These shares were acquired through restricted stock units and sold under a Rule 10b5-1 trading plan. The sale follows a strong 77% return for KURA shares over the past year and com

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 02:09
Source
Investing.com South Africa
Investing.com Nigeria Direct company coverage

Form 4 Kura Oncology Inc For: 22 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Kura Oncology Inc. The filing was made on June 22nd and the article provides no further details beyond this announcement. The core content is simply the title and a repetition of the details within the body.

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 22:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan

Kura Oncology's Chief Medical Officer, Mollie Leoni, sold 84,929 shares of common stock on June 18, 2026, at a weighted average price of $9.8233 per share, totaling approximately $834,283. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 19,

Tone
Negative 28/100
Event
Market update
Published
22 Jun 2026 21:59
Source
Stock Titan
Stock Traders Daily Direct company coverage

Understanding the Setup: (KURA) and Scalable Risk

The article provides an analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting positive near-term sentiment that may counter a mid-term weak bias within a long-term strong trend. It points out that resistance is being tested and details specific trading strategies for differ

Tone
Positive 71/100
Event
Market update
Published
19 Jun 2026 00:10
Source
Stock Traders Daily
Stock Titan Direct company coverage

[144] Kura Oncology, Inc. SEC Filing

This article details a Form 144 SEC filing by Kura Oncology, Inc. for a proposed sale of securities. The filing indicates a sale of 84,929 shares of common stock with an aggregate market value of $812,770.53 through Morgan Stanley Smith Barney LLC on NASDAQ, dated June 18, 2026.

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 20:10
Source
Stock Titan
TradingKey Direct company coverage

Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Kura Oncology Inc (KURA) has an earnings forecast score of 8.25. Analysts have given KURA a strong buy rating with an average price target of $28.00, ranging from $16.00 to $76.00. The company's expected revenue for the next quarter is $20.84 million, with an expected EPS of -$0.

Tone
Positive 70/100
Event
Earnings
Published
18 Jun 2026 10:10
Source
TradingKey